Advertisements
Read Time:15 Second
Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of full approval of Paxlovid, stating that the benefits outweigh any risks of the drug for treatment of mild to moderate Covid-19 in adults who are at high risk for severe disease, including hospitalization and death.
Happy
0
0 %
Sad
0
0 %
Excited
0
0 %
Sleepy
0
0 %
Angry
0
0 %
Surprise
0
0 %